ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 35459782

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

Odeniyide P and 14 others. Oncogene, 2022. Cited by 39 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Papers, record 35459782. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35459782

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
PubMed
Journal
Oncogene
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
2.81
iCite
Revised in PubMed
2026-11-02
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Odeniyide PPatiencehttps://orcid.org/0000-0002-9783-1657
2Yohe MEMarielle E
3Pollard KKai
4Vaseva AVAngelina V
5Calizo AAna
6Zhang LLindy
7Rodriguez FJFausto Jhttps://orcid.org/0000-0001-8662-1219
8Gross JMJohn M
9Allen ANAmy N
10Wan XXiaolin

1 to 10 of 15Source PubMed

See all 15 authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RhabdomyosarcomaMajor topic
Rhabdomyosarcoma, EmbryonalMajor topic
Farnesyltranstransferase
Genes, ras
Humans
Prenylation
Proto-Oncogene Proteins p21(ras)

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
P50 CA211015NCI NIH HHSUnited StatesP50CA211015PubMedNIH RePORTER
R37 CA262657NCI NIH HHSUnited StatesR37CA262657PubMed and NIHNIH RePORTER
ZIABC011892NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in35,534,540Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.https://conductscience.org/library/papers/35534540

Source PubMed

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118,701,506Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.Cancer Res2008https://conductscience.org/library/papers/18701506PubMed
222,142,829Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.Clin Cancer Res2012https://conductscience.org/library/papers/22142829PubMed
32,547,513ras oncogenes in human cancer: a review.Cancer Res1989https://conductscience.org/library/papers/2547513PubMed
425,323,927Drugging the undruggable RAS: Mission possible?Nat Rev Drug Discov2014https://conductscience.org/library/papers/25323927PubMed
512,642,680Ras family signaling: therapeutic targeting.Cancer Biol Ther2002https://conductscience.org/library/papers/12642680PubMed
631,227,505Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.Clin Cancer Res2019https://conductscience.org/library/papers/31227505PubMed
729,808,010Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.Nat Med2018https://conductscience.org/library/papers/29808010PubMed
830,683,722Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.Proc Natl Acad Sci U S A2019https://conductscience.org/library/papers/30683722PubMed
930,045,908SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.Cancer Discov2018https://conductscience.org/library/papers/30045908PubMed
1010,550,163Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.J Clin Oncol1999https://conductscience.org/library/papers/10550163PubMed

1 to 10 of 56

See all 56 references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
42,958,559Targeted protein degradation in cancer: strategies for undruggable targets and progress towards clinical translation.Biomark Res2026https://conductscience.org/library/papers/42958559PubMed
41,899,494Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.Cancers (Basel)2026https://conductscience.org/library/papers/41899494PubMed
41,671,396Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Cancer Res2026https://conductscience.org/library/papers/41671396PubMed
41,346,770Integrative computational approach to farnesyltransferase inhibition toward anti-liver cancer drug candidate from Syzygium cumini essential oils.Mol Biol Res Commun2026https://conductscience.org/library/papers/41346770PubMed
41,340,466Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Mol Cancer Ther2026https://conductscience.org/library/papers/41340466PubMed
41,339,438The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells.Nat Commun2025https://conductscience.org/library/papers/41339438PubMed
41,258,582Farnesyltransferase inhibitors decrease matrix-vesicle-mediated mineralization in SaOS-2 cells.Mol Biol Rep2025https://conductscience.org/library/papers/41258582PubMed
41,148,168PCSK5M452I Is a Recessive Hypomorph Exclusive to MCF10DCIS.com Cells.Mol Cancer Res2026https://conductscience.org/library/papers/41148168PubMed
40,956,876Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers.Sci Signal2025https://conductscience.org/library/papers/40956876PubMed
40,862,711Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma.Cells2025https://conductscience.org/library/papers/40862711PubMed

1 to 10 of 30

See all 30 cited by

Genes32

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
B2M567PubTator's text mininghttps://conductscience.org/library/genes/567NCBI Gene
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CENPE1,062PubTator's text mininghttps://conductscience.org/library/genes/1062NCBI Gene
CENPF1,063PubTator's text mininghttps://conductscience.org/library/genes/1063NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF2AK39,451PubTator's text mininghttps://conductscience.org/library/genes/9451NCBI Gene
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FOXO12,308PubTator's text mininghttps://conductscience.org/library/genes/2308NCBI Gene
GNAS2,778PubTator's text mininghttps://conductscience.org/library/genes/2778NCBI Gene

1 to 10 of 32

See all 32 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35459782

GET https://conductscience.org/api/papers/v1/35459782/references?page=2

API referenceFor AI assistants